A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

开始日期2026-12-01

申办/合作机构

思路迪科技（上海）有限公司

ChiCTR2600119589

/ SuspendedN/AIIT

A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China

开始日期2026-06-01

申办/合作机构

浙江省肿瘤医院

ChiCTR2600123538

/ Not yet recruiting临床2期IIT

To evaluate the efficacy and safety of HL-1186 tablets for abdominal postoperative analgesia in a multicenter, randomized, double-blind, placebo-positive parallel controlled phase Ⅱ/Ⅲ clinical trial

开始日期2026-05-06

申办/合作机构

中南大学湘雅三医院

[+1]

100 项与盐酸羟考酮相关的临床结果

登录后查看更多信息

100 项与盐酸羟考酮相关的转化医学

登录后查看更多信息

100 项与盐酸羟考酮相关的专利（医药）

登录后查看更多信息

4,212

项与盐酸羟考酮相关的文献（医药）

2026-05-01·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The influence of UV filters (Oxybenzone and Avobenzone) on lipid monolayers, with consideration of the role of lipid structure and monolayer composition

Article

作者: Wyżga, Beata ; Olechowska, Karolina ; Skóra, Magdalena ; Hąc-Wydro, Katarzyna

The widespread use of UV filters and their release into the environment raise concerns due to their potential harmful effects on living organisms. Consequently, the toxicity and bioaccumulation capacity of UV filters are currently the subject of an intensive study. This work investigates the effect of two UV filters, Oxybenzone (Oxy) and Avobenzone (Avo), on the monolayers formed by the lipids typical for bacteria membranes, as well as on the mixed lipid films imitating E. coli and S. aureus membranes. The studied lipids differed in their hydrophobic and hydrophilic parts, enabling discussion of the effect of lipid structure and monolayer composition on UV filter affinity for the model systems. The experiments involved surface pressure/area measurements, penetration studies, and Brewster angle microscopy investigations. The in vitro tests on various bacteria strains were also performed. The studied UV filters showed varying affinity for the lipids and membrane models tested. Avo modified the properties of the investigated systems more strongly than Oxy. However, the most important conclusion was that filters' affinity for lipid systems depended on both the structure of the lipids, which determines monolayer properties, and the monolayer's organization. The presence of condensed domains dispersed in a more fluid matrix was a particularly important factor in enhancing the incorporation of Avo and its fluidizing effect. The toxic effects of Avo and Oxy were not directly linked to their interactions with lipids. Nevertheless, the affinity of these compounds for lipids and membrane domains may facilitate their accumulation in the cells of living organisms.

2026-05-01·JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Pre-emptive Oxycodone versus Sufentanil for Acute and Delayed Pain after Transcatheter Arterial Chemoembolization: A Randomized Controlled Trial with Inflammatory Biomarker Analysis

Article

作者: Chen, Yu ; Zu, Qing-Quan ; Zhou, Wei-Zhong ; Xu, Bo-Jing ; Wu, Wen-Tao ; Liu, Sheng ; Shi, Hai-Bin ; Hang, Yu ; Li, Bing

PURPOSE:

To compare the effectiveness of pre-emptive oxycodone versus sufentanil for acute and delayed pain control after transcatheter arterial chemoembolization (TACE).

MATERIALS AND METHODS:

In this prospective, double-blind trial, 40 patients scheduled for TACE were randomized to receive intravenous oxycodone (0.1 mg/kg) or sufentanil (0.1 μg/kg) 15 minutes before TACE. Pain intensity was assessed using a visual analog scale (VAS) during acute (0-24 hours) and delayed (Days 2-7) phases. Inflammatory biomarkers (white blood cell count, neutrophil percentage, C-reactive protein, and interleukin [IL]-6) were measured at baseline and 24 hours after TACE. The primary outcome was the highest acute-phase VAS scores; secondary outcomes included delayed-phase pain, changes in inflammatory biomarkers, and adverse events.

RESULTS:

Oxycodone demonstrated superior analgesia, with lower intraprocedural VAS scores (median, 0 [interquartile range {IQR}, 0-1.0] vs 3.5 [IQR, 1.3-4.8]; P < .001) and reduced incidence of moderate-to-severe pain (5% vs 50%; P = .003). This benefit persisted at 1-6 hours after TACE (median, 0 [IQR, 0-1.0] vs 2 [IQR, 0-3.0]; P = .042). During the delayed phase, oxycodone maintained lower pain scores (median, 0 [IQR, 0-0] vs 0 [IQR, 0-3.8]; P = .042) and fewer episodes of moderate pain (0% vs 25%; P = .047). IL-6 elevation was greater in patients developing delayed pain (671.16% vs 135.97% increase; P = .030). Adverse event rates were comparable.

CONCLUSIONS:

Pre-emptive oxycodone provided more effective acute and delayed pain control after TACE compared with sufentanil, with comparable safety. The association between IL-6 elevation and delayed pain suggests an inflammatory pain component, supporting further investigation of combined opioid and anti-inflammatory strategies.

2026-04-01·WATER RESEARCH

Ice-covered lakes, hidden threats: Seasonal fate and risks of antibiotics and PAHs

Article

作者: Liu, Xuemei ; Jiang, Lili ; Zhang, Guangxin ; Ju, Hanyu ; Zhang, Jingjie ; de Goede, Erik ; Wang, Peixin ; Li, Jie

In cold-region lakes, the spatiotemporal dynamics of pollutants are controlled by complex and interacting physical, chemical, and biological processes, necessitating systematic quantitative assessment. However, this field has received less than 2% of total research attention in the freshwater literature, revealing a substantial knowledge gap. Moreover, different classes of emerging contaminants often display distinct risk patterns within the same aquatic ecosystem. To address this gap, we investigated Chagan Lake -a representative ice-covered lake in Northeast China-using antibiotics and polycyclic aromatic hydrocarbons (PAHs) as typical case pollutants. A seasonally coupled hydrodynamic-pollutant fate model was developed to simulate the full annual cycle of ice formation, coverage, thawing, and melting, with oxytetracycline (OXY) and naphthalene (NAP) selected as representative compounds. The model was rigorously calibrated and validated against 2021 field observations, achieving Kling-Gupta efficiency (KGE) values above 0.50 for pollutant concentrations, indicating robust predictive capability. Scenario analyses were then conducted: (1) water diversion altered hydrodynamic regimes and promoted long-term pollutant attenuation; (2) external load reduction combined with sediment dredging produced cross-seasonal "source-sink" regulation; and (3) NAP exhibited a threshold-type response, with risks sharply increasing once external inputs surpassed sediment buffering capacity. Comparative analysis indicated that OXY consistently posed ecological risk, whereas risks associated with NAP generally remained low except under threshold exceedance scenarios. These findings highlight the interplay between contaminant properties and seasonal hydrological processes, providing a transferable framework for pollution control and risk prevention in ice-affected lake ecosystems.

386

项与盐酸羟考酮相关的新闻（医药）

2026-05-12

·BioSpace

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(News - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") , is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the " Initial Tranche ") of its previously announced $1,000,000 non-brokered private placement (the " Offering "), which Initial Tranche consisted of the issuance of 13,600,000 units (each, a " Unit ") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $340,000. Each Unit is comprised of one (1) common share (each, a " Share ") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a " Warrant "). Each Warrant entitles the holder thereof to purchase an additional Share (each, a " Warrant Share ") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of the Initial Tranche (the " Initial Tranche Closing "), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.10 or greater on the Canadian Securities Exchange (" CSE ") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30 th day after the date on which the news release is disseminated (the " Acceleration Right "). In connection with the Initial Tranche Closing, the Company paid finders fees to three eligible finders comprised of $23,600 in cash and issued 944,000 finder's warrant (each, a " Finder's Warrant "). The Finder's Warrant are exercisable into one additional Share at an exercise price of $0.05 per Share for two years from the Initial Tranche Closing, subject to the Acceleration Right. The Company intends to use the aggregate gross proceeds of the Initial Tranche to pay outstanding payables, for operating expenses and for general working capital purposes. PreveCeutical intends to close a second tranche for the remainder of the Offering in the coming weeks. All securities issued in relation to the Initial Tranche are subject to a hold period expiring four months and one day after the Initial Tranche Closing, in accordance with applicable securities laws. The securities issued under the Offering, including those in the Initial Tranche, have not been and will not be registered under the United States Securities Act of 1933 , as amended (the " Securities Act "), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Initial Tranche and the closing of a subsequent tranche of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Initial Tranche may not be used as stated in this news release, that the Company may not be able to close a subsequent tranche of the Offering and those additional risks set out in the Company's public documents filed on SEDAR+ at . Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit

临床研究

2026-05-10

·药研途

一周新药 | 全球新药速览（2026年05月04日~05月09日）

一、获批上市药物 1. Sotyktu（deucravacitinib）——欧盟首个用于银屑病关节炎的TYK2抑制剂生产厂家：百时美施贵宝（Bristol-Myers Squibb）获批时间：2026年5月8日获批国家/地区：欧盟（欧洲委员会批准）获批适应症：用于治疗成人活动性银屑病关节炎（PsA）。可单独使用，适用于对既往改善病情抗风湿药（DMARD）治疗应答不足或不耐受的患者。作用机制：选择性酪氨酸激酶2（TYK2）抑制剂，每日一次口服给药。临床研究亮点：此次获批基于两项关键性III期临床试验——POETYK PsA-1和POETYK PsA-2的积极结果。Sotyktu是欧盟首个获批用于治疗活活动性银屑病关节炎的TYK2抑制剂。 2. 库莫西利胶囊——全球首个CDK2/4/6抑制剂获批乳腺癌新适应症中英文名称：库莫西利胶囊（中国生物制药自主研发）生产厂家：中国生物制药下属企业正大天晴获批时间：2026年5月6日获批国家/地区：中国（国家药品监督管理局NMPA批准）获批适应症：联合氟维司群用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌患者的初始治疗。这是该药获批上市的第2个适应症。作用机制：全球首个CDK2/4/6抑制剂，通过抑制细胞周期蛋白依赖性激酶2/4/6，阻断肿瘤细胞增殖。临床研究亮点：本次新增适应症获批基于CULMINATE-2临床研究。结果显示，库莫西利联合氟维司群一线治疗HR+/HER2-晚期乳腺癌，客观缓解率达59.3%，疾病进展或死亡风险降低44%。 3. 阿贝西利片剂仿制药——首款获批上市药物名称：阿贝西利片（Abemaciclib）仿制药生产厂家：科睿药业获批时间：2026年5月6日获批国家/地区：中国（国家药监局官网公示）获批适应症：与原研药一致，用于乳腺癌治疗。原研阿贝西利（礼来开发）是一款CDK4/6抑制剂，目前已获批4项适应症。作用机制：通过抑制细胞周期蛋白D诱导乳腺癌细胞衰老和凋亡。临床研究亮点：原研阿贝西利片剂于2017年9月首次在美国获批上市，2020年12月在中国获批。据礼来2025年报显示，阿贝西利全球销售额达到57.23亿美元，是目前销售额最高的的CDK4/6抑制剂。此次科睿药业的仿制药为首款获批的阿贝西利片剂仿制药。 4. 苑东生物氨酚羟考酮缓释片：国内首家获批药物名称：氨酚羟考酮缓释片（Oxycodone/Acetaminophen Extended-Release Tablets）生产厂家：成都苑东生物制药股份有限公司获批时间：2026年5月6日获批地区：中国（NMPA）获批适应症：术后中重度疼痛治疗作用机制：本品为盐酸羟考酮（阿片受体激动剂）与对乙酰氨基酚（解热镇痛药）的复方缓释制剂。采用速释层+缓释层双层技术设计，速释层实现快速镇痛起效，缓释层维持12小时长效平稳镇痛。同时采用物理屏障技术有效防止阿片类药物滥用。临床研究亮点：注册分类为化药2.2类（含已知活性成分的新剂型），国内首家获批的阿片复方缓控释制剂，填补国内市场空白，兼顾快速起效与长效镇痛，且具有防滥用特性 5. Ocrevus新适应症：首个儿童多发性硬化高效疗法药物名称：ocrelizumab（商品名：Ocrevus）生产厂家：Genentech（罗氏集团成员）获批时间：2026年5月8日获批地区：美国（FDA）获批适应症：10岁及以上儿童复发-缓解型多发性硬化（RRMS）作用机制：ocrelizumab是一种人源化抗CD20单克隆抗体，通过选择性靶向并耗竭表达CD20的B细胞，减少B细胞介导的炎症反应和神经损伤，从而延缓多发性硬化的疾病进展。临床进展亮点：Ocrevus此前已获批用于成人复发型MS和原发进展型MS 此次儿童适应症获批为10岁及以上RRMS患儿提供了首个获批的高效抗CD20治疗选择进一步巩固Ocrevus在多发性硬化全年龄段治疗中的领先地位。 6. Bizengri获批：罕见胆管癌迎来精准靶向治疗药物名称：zenocutuzumab-zbco（商品名：Bizengri）生产厂家：Partner Therapeutics / Merus N.V. 获批时间：2026年5月8日获批地区：美国（FDA）获批适应症：携带NRG1基因融合的晚期、不可切除或转移性胆管癌成年患者（既往全身治疗后疾病进展）作用机制：zenocutuzumab是一种双特异性抗体，可同时结合HER2和HER3受体，阻断NRG1融合蛋白驱动的HER3/HER2异源二聚化及下游信号通路，从而抑制肿瘤生长。临床研究亮点：基于I/II期eNRGy试验（NCT02912949）数据获批19例可评估疗效患者中，确认客观缓解率（ORR）达36.8%（95% CI: 16.3-61.6）缓解持续时间（DOR）范围2.8至12.9个月曾获FDA优先审评、突破性疗法认定和孤儿药认定，比目标日期提前约5个月获批。二、申报上市药物 1. 芦康沙妥珠单抗（sac-TMT，SKB264/MK-2870）——TROP2 ADC联合PD-1一线治疗NSCLC申报上市中英文名称：芦康沙妥珠单抗（sac-TMT，亦称SKB264/MK-2870）生产厂家：科伦博泰申报时间：2026年5月8日申报国家/地区：中国（CDE受理，已纳入优先审评）申报适应症：联合默沙东的PD-1单抗帕博利珠单抗，一线治疗PD-L1肿瘤比例分数（TPS）≥1%的EGFR基因突变阴性和ALK阴性的局部晚期或转移性非小细胞肺癌。作用机制：TROP2抗体药物偶联物（ADC）临床研究亮点：本次受理是基于OptiTROP-Lung05注册III期研究的积极结果。这是芦康沙妥珠单抗获NMPA受理的第五项适应症上市申请。 2. 佐来曲替尼口崩片（Zurletrectinib, ICP-723）——新一代TRK抑制剂申报儿童实体瘤新适应症中英文名称：佐来曲替尼口崩片（Zurletrectinib, ICP-723）生产厂家：诺诚健华申报时间：2026年5月8日申报国家/地区：中国（CDE受理，已纳入优先审评和「儿童抗肿瘤药物研发鼓励试点计划（星光计划）」）申报适应症：用于治疗携带神经营养酪氨酸受体激酶（NTRK）融合基因的儿童实体瘤患者（2岁至12岁）。作用机制：新一代TRK抑制剂临床研究亮点：佐来曲替尼于2025年12月首次获得NMPA批准上市，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者，成为首款获批的国产TRK抑制剂。此次为新增儿童适应症申报。 3. 培阿普特玻璃体内注射液（Avacincaptad pegol）——国内首个申报的AMD继发地图样萎缩治疗药物中英文名称：培阿普特玻璃体内注射液（Avacincaptad pegol）生产厂家：安斯泰来（Astellas）申报时间：2026年5月7日申报国家/地区：中国（CDE网站显示申报上市，根据3月优先审评动态，适应症已明确）申报适应症：用于治疗继发于年龄相关性黄斑变性（AMD）的地图样萎缩（GA）。该药物有望成为国内首个获批的AMD继发GA治疗药物。作用机制：一种旨在抑制补体C5蛋白的聚乙二醇化RNA适配体。临床研究亮点：2023年5月，安斯泰来以59亿美元收购Iveric Bio获得该药权益。2023年8月，该药（商品名：Izervay）获FDA批准上市，初始方案为每月给药1次、持续最多1年。2025年2月，FDA批准取消给药持续时间限制，为临床管理提供了更大灵活性。三、III期临床达到主要终点 1. I124 evuzamitide（AT-01）——放射性示踪剂诊断心脏淀粉样变性III期成功药物名称：I124 evuzamitide（又称AT-01）生产厂家：拜耳（Bayer）关键时间：2026年5月7日公布积极顶线数据研究阶段：III期临床研究（REVEAL研究）适应症：用于诊断心脏淀粉样变性作用机制：PET/CT放射性示踪剂临床研究亮点：REVEAL研究是一项多中心、开放标签、单臂的III期临床试验，在美国19个医疗中心开放标签、单臂的III期临床试验，在美国19个医疗中心开展，共评估了170名疑似患有心脏淀粉样变性的成年患者。研究基于视觉扫描解释，成功达到了敏感性（识别患病个体的能力）和特异性（识别未患病个体的能力）的主要终点。 2. Elegrobart——皮下注射抗IGF-1R抗体治疗慢性甲状腺眼病III期成功药物名称：Elegrobart（尚无中文名）生产厂家：Viridian Therapeutics 关键时间：2026年5月5日/5月6日公布积极顶线数据研究阶段：III期临床试验（REVEAL-2）适应症：用于治疗慢性甲状腺眼病（TED）作用机制：靶向胰岛素样生长因子-1受体（IGF-1R）的单克隆抗体，通过皮下注射给药，半衰期延长。临床研究亮点：REVEAL-2研究评估了每4周一次（Q4W）和每8周一次（Q8W）两种给药方案，并与安慰剂比较。以高度统计学显著性（p<0.0001）达到美国FDA和欧洲药品管理局（EMA）要求的主要终点。在Q4W和Q8W治疗组中，均以高度统计学显著性达到所有眼球突出关键次要终点。Q4W治疗组在第24周显示出具有统计学显著性的复视应答率。总体而言，无论基线临床活动评分（CAS）如何，疗效均基本一致。 3. Opzelura（芦可替尼乳膏，ruxolitinib cream 1.5%）研发企业：Incyte 研究进度：TRuE-AD4 III期24周数据公布（2026 EADV Symposium）目标适应症：中等程度特应性皮炎（受累BSA 10-20%）作用机制：局部JAK1/JAK2抑制剂，抑制特应性皮炎相关炎症细胞因子信号通路。临床研究亮点：24周时，84.3%患者达到EASI75，70.6%达到IGA治疗成功。平均受累体表面积持续维持在2.5%，64.7%患者瘙痒改善≥4分。支持在中等程度AD患者中长期维持治疗的持续获益，有望推动欧盟适应症拓展。 4. asundexian（口服Factor XIa抑制剂）研发企业：Bayer 研究进度：OCEANIC-STROKE III期新分析结果（ESOC 2026大会报告）目标适应症：非心源性缺血性卒中或高风险TIA的二级预防作用机制：选择性抑制凝血因子XIa，阻断病理性血栓形成而保留正常止血功能。临床研究亮点：新分析显示：asundexian组缺血性卒中患者NIHSS评分≥8的比例低于安慰剂组（22.9% vs 30.3%, p=0.045）；致残性卒中发生率呈数值下降（2.1% vs 3.0%; csHR 0.69）；此前研究已发表于《新英格兰医学杂志》，达到主要疗效与安全性终点。参考文献： [1]各公司官网 [2]NMPA官网 [3]FDA官网本文中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。本公众号不对任何主体因使用本文内容而导致的任何损失承担责任。另外，因水平有限，不足之处在所难免，敬请谅解！

2026-05-07

·EINPresswire

ICAIE Releases New Infographic: The Growing Threat Posed By Illicit Trade of Counterfeit Medicines in Mexico

Diversification by Cartels into Pharmaceuticals Expands the Lucrative Illicit Trade in the Americas Drug cartels' illicit empires now include a growing dominance in the trafficking of fake medicines and counterfeit pharmaceuticals, a multi-billion illicit industry in Mexico and across the Americas.” — David M. Luna WASHINGTON, DC, UNITED STATES, May 7, 2026 / EINPresswire.com / -- ICAIE releases new May 2026 Infographic on illicit trade of counterfeit medicines in Mexico and the Americas by the drug cartels that have also been designated by the United States and Canada as Foreign Terrorist Organizations (FTOs) and Specially Designated Global Terrorists (SDGTs) for their armed violence, drug-fentanyl trafficking, illicit trade and other threats to their respective national security. The Cártel de Jalisco Nueva Generación (CJNG) and other Mexican cartels find diversification into the pharmaceutical sector very lucrative, earning hundreds of millions of dollars from fake, counterfeit, and diverted medicines. – COFEPRIS reports a 300% increase in falsified drug types since 2019. – AMIF estimates that 60% of medicines in Mexico are stolen, expired, falsified, or made without basic quality control. – A 2023 UCLA study found 1 in 3 border pharmacies sold fake meds—68% without prescriptions. – An LA Times investigation found 50%+ of opioid pills tested in Mexico were counterfeit, often containing fentanyl or meth. – Many of these fake pills often mimic Adderall, Xanax, OxyContin, and Percocet—and may contain fentanyl or xylazine. – 12 of 15 Adderall samples contained illicit substances—even in factory-sealed bottles. – In El Santuario, Guadalajara, cartels sell fake meds openly, costing the legal sector over $1B/year. – Vendors and pharmacists are often coerced into selling fakes alongside real medicines. – Many fake drugs target U.S. tourists, disguised as legitimate prescriptions. – Diverted medicines are real but sold illegally, often expired, stolen, or improperly stored. Find ICAIE May 2026 Infographic at: https://icaie.com/2026/05/illicit-trade-of-counterfeit-medicines-in-mexico-diversification-by-cartels-into- pharmaceuticals -expands-the-lucrative-illicit-trade-in-the-americas/ David Manuel Luna International Coalition Against Illicit Economies (ICAIE) email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 项与盐酸羟考酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00847	盐酸羟考酮	N02AA05	DBSALT000277

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癌症疼痛	日本	Shionogi Pharma Co., Ltd.	2012-05-01
急性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
慢性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
疼痛	美国	Roxane Laboratories, Inc.	1998-10-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腰痛	临床3期	美国	Egalet Ltd.	2016-03-01
脊椎骨关节炎	临床3期	美国	Purdue Pharma LP	2004-04-01
镇痛	临床1期	美国	Purdue Pharma LP	2010-07-01
镇痛	临床1期	澳大利亚	Purdue Pharma LP	2010-07-01
镇痛	临床1期	芬兰	Purdue Pharma LP	2010-07-01
镇痛	临床1期	新西兰	Purdue Pharma LP	2010-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07223450 (CTgov)	临床1期	-	8	oxycodone (Group: Oral)	鹽簾壓憲獵範鹹齋遞觸(夢範蓋網鹽積範蓋顧憲) = 鬱餘範膚顧窪齋網淵鹽齋顧鹹網襯範淵鑰範壓 (壓遞醖顧構衊繭鑰醖淵, 1954.6) 更多	-	2026-05-06
				oxycodone (Group Intranasal)	鹽簾壓憲獵範鹹齋遞觸(夢範蓋網鹽積範蓋顧憲) = 範簾願網餘簾觸廠鹽簾齋顧鹹網襯範淵鑰範壓 (壓遞醖顧構衊繭鑰醖淵, 1824.8) 更多
NCT06041425 (Pubmed \| J Vasc Interv Radiol)	临床4期	疼痛	40	Oxycodone	膚選醖網繭鹽膚壓簾淵(網觸齋築憲網夢衊艱襯) = Adverse event rates were comparable. 醖鏇廠壓積構築鑰簾遞 (糧範淵壓餘齋廠鬱簾壓 )	积极	2026-05-01
				Sufentanil
NCT03574792 (CTgov)	临床2期	疼痛 \| 头颈部皮肤鳞状细胞癌	62	Quality-of-Life Assessment+Oxycodone+Methadone+Gabapentin (Arm I (Gabapentin, Methadone, Oxycodone))	窪憲淵襯艱鹽襯壓廠構(衊觸網觸願憲蓋憲蓋繭) = 壓顧觸積遞遞繭積糧廠鬱鹽網鏇鹽夢夢觸鏇蓋 (獵遞淵網淵選鏇餘壓膚, 10) 更多	-	2026-04-16
				Quality-of-Life Assessment+Oxycodone+Methadone+Venlafaxine+Gabapentin (Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine))	窪憲淵襯艱鹽襯壓廠構(衊觸網觸願憲蓋憲蓋繭) = 網觸鏇願願構襯艱鑰簾鬱鹽網鏇鹽夢夢觸鏇蓋 (獵遞淵網淵選鏇餘壓膚, 17) 更多
NCT05974501 (CTgov)	临床4期	关节置换术并发症 \| 膝关节炎 \| 术后疼痛	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	衊選窪廠製鬱淵餘糧範(範選鹹壓鹹壓壓繭繭觸) = 觸範膚繭艱鏇淵積獵願鹽範廠簾鬱壓獵範範鑰 (鹹齋淵廠積顧夢鏇蓋觸, 淵艱齋鹹鏇醖觸淵願膚 ~ 獵構齋遞淵憲鬱夢醖獵) 更多	-	2025-02-12
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	衊選窪廠製鬱淵餘糧範(範選鹹壓鹹壓壓繭繭觸) = 壓積鏇鏇淵構夢糧餘鹽鹽範廠簾鬱壓獵範範鑰 (鹹齋淵廠積顧夢鏇蓋觸, 淵觸範願夢觸齋願蓋鏇 ~ 鏇鹹艱窪選鹹簾憲艱遞) 更多
NCT01458015 (CTgov)	临床4期	神经痛	3	oxycodone+tapentadol (Oxycodone)	廠範醖獵網鹽醖積鑰鹹(積襯鹽構餘壓夢憲醖糧) = 齋壓齋襯願築齋糧襯繭憲鑰鑰艱鹽繭窪遞網壓 (範餘築顧廠餘鬱範醖憲, 夢選繭襯窪遞鏇齋積願 ~ 範構選醖獵鑰獵齋構鏇) 更多	-	2024-12-17
				oxycodone+tapentadol (Tapentadol)	廠範醖獵網鹽醖積鑰鹹(積襯鹽構餘壓夢憲醖糧) = 獵製獵鏇襯製鏇願遞糧憲鑰鑰艱鹽繭窪遞網壓 (範餘築顧廠餘鬱範醖憲, 鏇壓積蓋構顧鬱淵鏇顧 ~ 積淵選積襯醖簾壓獵遞) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	憲齋積醖鹽鬱遞遞製願(齋構網夢襯鹽範窪網繭) = 壓衊鬱廠鏇衊範窪築積遞網鹽選醖淵憲齋糧膚 (願廠遞積鬱糧遞糧網構, 夢積鹹構淵鏇衊築選遞 ~ 艱鹽積膚鏇襯製壓願鹽) 更多	-	2024-09-19
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	憲齋積醖鹽鬱遞遞製願(齋構網夢襯鹽範窪網繭) = 築繭夢淵築構顧齋艱鹽遞網鹽選醖淵憲齋糧膚 (願廠遞積鬱糧遞糧網構, 窪顧遞構製願範簾獵艱 ~ 鑰遞壓顧積夢艱遞糧衊) 更多
NCT04791761 (CTgov)	临床1/2期	术后疼痛	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	願鬱鑰網簾廠淵鬱構遞(糧膚鏇製艱築築鏇構積) = 製憲觸齋遞簾艱簾淵鬱鏇鑰夢網蓋鑰製壓觸選 (淵積壓構遞齋鹹醖願顧, 窪醖餘鹹窪艱願願構構 ~ 簾壓窪願築遞網糧製齋) 更多	-	2024-08-16
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	願鬱鑰網簾廠淵鬱構遞(糧膚鏇製艱築築鏇構積) = 襯衊夢築鑰窪鏇網艱廠鏇鑰夢網蓋鑰製壓觸選 (淵積壓構遞齋鹹醖願顧, 廠夢願範憲鹹鑰衊遞網 ~ 齋鬱築蓋醖齋獵構餘獵) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	範窪顧鹽夢鹽夢範壓淵(餘範淵膚積襯繭築壓鹽) = 觸膚淵積廠醖鏇膚選鹹襯蓋醖憲網鑰選壓範壓 (鏇鏇餘憲鹽積觸衊網築, 廠醖選鏇鬱獵鑰齋積鬱 ~ 範壓顧願夢鏇簾築鹹夢) 更多	-	2024-07-08
				Percocet (Control)	範窪顧鹽夢鹽夢範壓淵(餘範淵膚積襯繭築壓鹽) = 鹽鏇構願鏇衊窪醖艱鹽襯蓋醖憲網鑰選壓範壓 (鏇鏇餘憲鹽積觸衊網築, 餘襯顧襯獵網淵築選齋 ~ 範憲製築鹹餘獵艱選製) 更多
NCT03612713 (CTgov)	早期临床1期	药物滥用	20	Oxycodone (Oxycodone Run)	糧醖糧鏇糧簾繭鑰觸觸(簾壓醖淵選廠積醖積鏇) = 憲衊願獵積繭憲蓋糧膚鑰構簾鹹憲顧糧壓窪鏇 (選窪遞選蓋顧齋網築膚, 1.37) 更多	-	2024-03-08
				placebo (Placebo Run)	糧醖糧鏇糧簾繭鑰觸觸(簾壓醖淵選廠積醖積鏇) = 鹽鹹廠鬱夢廠範醖壓淵鑰構簾鹹憲顧糧壓窪鏇 (選窪遞選蓋顧齋網築膚, 2.46) 更多
NCT04122443 (CTgov)	临床4期	肌肉骨骼疼痛	393	Acetaminophen+Ibuprofen (Ibuprofen and Then Acetaminophen (Stage 2))	選壓願網簾鏇願糧選網(網範繭鹽膚鹹憲繭壓淵) = 艱網積獵壓艱積餘獵齋蓋壓鹽齋廠鬱夢壓獵鏇 (糧鬱壓簾鏇艱衊鏇繭築, 2.4) 更多	-	2024-02-28
				Acetaminophen+Oxycodone+Ibuprofen (Ibuprofen and Then Oxycodone/Acetaminophen (Stage 2))	選壓願網簾鏇願糧選網(網範繭鹽膚鹹憲繭壓淵) = 夢網築鹹鑰遞範觸鑰窪蓋壓鹽齋廠鬱夢壓獵鏇 (糧鬱壓簾鏇艱衊鏇繭築, 2.6) 更多